During the past decade, Oklahoma Institute of Allergy and Asthma Clinical Research conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 9 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma Institute of Allergy and Asthma Clinical Research" #1 sponsor was "Aimmune Therapeutics, Inc." with 3 trials, followed by "Baxalta now part of Shire" with 3 trials sponsored, "Grifols Therapeutics LLC" with 3 trials sponsored, "Meda Pharmaceuticals" with 3 trials sponsored and "ADMA Biologics, Inc." with 3 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Institute of Allergy and Asthma Clinical Research" #1 collaborator was "Atlantic Research Group" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Institute of Allergy and Asthma Clinical Research" are "Asthma" (3 trials), "Peanut Allergy" (3 trials), "Primary Immunodeficiency" (3 trials), "Primary Immunodeficiency Diseases (PID)" (3 trials) and "Allergic Rhinitis" (1 trials). Many other conditions were trialed in "Oklahoma Institute of Allergy and Asthma Clinical Research" in a lesser frequency.

Most popular intervention types in "Oklahoma Institute of Allergy and Asthma Clinical Research" are "Biological" (14 trials), "Drug" (9 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "AR101" (3 trials), "Bivigam" (2 trials), "HYQVIA" (2 trials) and "IGSC 20%" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Institute of Allergy and Asthma Clinical Research" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Oklahoma Institute of Allergy and Asthma Clinical Research". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Oklahoma Institute of Allergy and Asthma Clinical Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Institute of Allergy and Asthma Clinical Research, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".